Biotechnology
Compare Stocks
2 / 10Stock Comparison
OMER vs IQV
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
OMER vs IQV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $1.04B | $29.95B |
| Revenue (TTM) | $0.00 | $16.63B |
| Net Income (TTM) | $-121M | $1.39B |
| Gross Margin | — | 26.1% |
| Operating Margin | — | 13.9% |
| Forward P/E | — | 13.9x |
| Total Debt | $207M | $16.17B |
| Cash & Equiv. | $3M | $1.98B |
OMER vs IQV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Omeros Corporation (OMER) | 100 | 99.7 | -0.3% |
| IQVIA Holdings Inc. (IQV) | 100 | 118.0 | +18.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OMER vs IQV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OMER carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.79
- Lower volatility, beta 0.79, current ratio 1.69x
- Beta 0.79, current ratio 1.69x
IQV is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 5.9%, EPS growth 4.7%, 3Y rev CAGR 4.2%
- 167.5% 10Y total return vs OMER's 19.8%
- 8.3% margin vs OMER's -4.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.4% revenue growth vs IQV's 5.9% | |
| Quality / Margins | 8.3% margin vs OMER's -4.8% | |
| Stability / Safety | Beta 0.79 vs IQV's 1.33 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +133.9% vs IQV's +20.7% | |
| Efficiency (ROA) | 4.7% ROA vs OMER's -53.9%, ROIC 8.7% vs -72.4% |
OMER vs IQV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
OMER vs IQV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
OMER leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IQV and OMER operate at a comparable scale, with $16.6B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $16.6B |
| EBITDAEarnings before interest/tax | -$127M | $3.5B |
| Net IncomeAfter-tax profit | -$121M | $1.4B |
| Free Cash FlowCash after capex | -$105M | $2.7B |
| Gross MarginGross profit ÷ Revenue | — | +26.1% |
| Operating MarginEBIT ÷ Revenue | — | +13.9% |
| Net MarginNet income ÷ Revenue | — | +8.3% |
| FCF MarginFCF ÷ Revenue | — | +16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +8.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +16.1% | +15.0% |
Valuation Metrics
OMER leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.0B | $29.9B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $44.1B |
| Trailing P/EPrice ÷ TTM EPS | -5.49x | 22.51x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.89x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.56x |
| EV / EBITDAEnterprise value multiple | — | 12.87x |
| Price / SalesMarket cap ÷ Revenue | — | 1.84x |
| Price / BookPrice ÷ Book value/share | — | 4.62x |
| Price / FCFMarket cap ÷ FCF | — | 14.60x |
Profitability & Efficiency
IQV leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), IQV scores 4/9 vs OMER's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +22.1% |
| ROA (TTM)Return on assets | -53.9% | +4.7% |
| ROICReturn on invested capital | -72.4% | +8.7% |
| ROCEReturn on capital employed | -64.8% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 2.44x |
| Net DebtTotal debt minus cash | $204M | $14.2B |
| Cash & Equiv.Liquid assets | $3M | $2.0B |
| Total DebtShort + long-term debt | $207M | $16.2B |
| Interest CoverageEBIT ÷ Interest expense | -5.80x | 3.10x |
Total Returns (Dividends Reinvested)
OMER leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OMER five years ago would be worth $8,445 today (with dividends reinvested), compared to $7,632 for IQV. Over the past 12 months, OMER leads with a +133.9% total return vs IQV's +20.7%. The 3-year compound annual growth rate (CAGR) favors OMER at 43.7% vs IQV's -2.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -9.5% | -21.7% |
| 1-Year ReturnPast 12 months | +133.9% | +20.7% |
| 3-Year ReturnCumulative with dividends | +196.6% | -7.0% |
| 5-Year ReturnCumulative with dividends | -15.5% | -23.7% |
| 10-Year ReturnCumulative with dividends | +19.8% | +167.5% |
| CAGR (3Y)Annualised 3-year return | +43.7% | -2.4% |
Risk & Volatility
OMER leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
OMER is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OMER currently trades 84.0% from its 52-week high vs IQV's 71.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 1.33x |
| 52-Week HighHighest price in past year | $17.65 | $247.05 |
| 52-Week LowLowest price in past year | $2.95 | $134.65 |
| % of 52W HighCurrent price vs 52-week peak | +84.0% | +71.4% |
| RSI (14)Momentum oscillator 0–100 | 70.0 | 58.4 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 1.6M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates OMER as "Buy" and IQV as "Buy". Consensus price targets imply 169.7% upside for OMER (target: $40) vs 27.9% for IQV (target: $226).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $225.63 |
| # AnalystsCovering analysts | 19 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.1% | +4.2% |
OMER leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). IQV leads in 1 (Profitability & Efficiency).
OMER vs IQV: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is OMER or IQV a better buy right now?
IQVIA Holdings Inc.
(IQV) offers the better valuation at 22. 5x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate Omeros Corporation (OMER) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OMER or IQV?
Over the past 5 years, Omeros Corporation (OMER) delivered a total return of -15.
5%, compared to -23. 7% for IQVIA Holdings Inc. (IQV). Over 10 years, the gap is even starker: IQV returned +167. 5% versus OMER's +19. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OMER or IQV?
By beta (market sensitivity over 5 years), Omeros Corporation (OMER) is the lower-risk stock at 0.
79β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 70% more volatile than OMER relative to the S&P 500.
04Which is growing faster — OMER or IQV?
On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc.
grew EPS 4. 7% year-over-year, compared to -43. 6% for Omeros Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OMER or IQV?
IQVIA Holdings Inc.
(IQV) is the more profitable company, earning 8. 3% net margin versus 0. 0% for Omeros Corporation — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 0. 0% for OMER. At the gross margin level — before operating expenses — IQV leads at 26. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is OMER or IQV more undervalued right now?
Analyst consensus price targets imply the most upside for OMER: 169.
7% to $40. 00.
07Which pays a better dividend — OMER or IQV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is OMER or IQV better for a retirement portfolio?
For long-horizon retirement investors, Omeros Corporation (OMER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
79)). Both have compounded well over 10 years (OMER: +19. 8%, IQV: +167. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between OMER and IQV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.